Long-term effectiveness and safety of omalizumab in pediatric and adult patients with moderate-to-severe inadequately controlled allergic asthma

Omalizumab is recommended as an add-on therapy in patients aged ≥6 years with inadequately controlled, moderate-to-severe persistent allergic asthma. The efficacy and safety of omalizumab treatment in allergic asthma clinical trials and its effectiveness in the real world have been reported in numer...

وصف كامل

التفاصيل البيبلوغرافية

المؤلفون الرئيسيون:	Nicola A. Hanania, MD, Robert Niven, MD, Pascal Chanez, MD, PhD, Deschildre Antoine, MD, PhD, Pascal Pfister, MD, Lorena Garcia Conde, MD, Xavier Jaumont, MD
التنسيق:	Artigo
اللغة:	Inglês
منشور في:	Elsevier 2022-10-01
سلاسل:	World Allergy Organization Journal
الموضوعات:	Allergic asthma Efficacy Long-term Omalizumab Safety Pediatric
الوصول للمادة أونلاين:	http://www.sciencedirect.com/science/article/pii/S1939455122000710
الوسوم:	إضافة وسم لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!